Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene: Complete Statistical AnalysisIndependent statistical analysis of Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval,…
- Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant: Complete Statistical AnalysisIndependent statistical analysis of Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults: Complete Statistical AnalysisIndependent statistical analysis of Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults: primary endpoint results, effect estimate with confidence…
- Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases: Complete Statistical AnalysisIndependent statistical analysis of Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer: primary endpoint results, effect estimate with confidence interval,…
- Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib): Complete Statistical AnalysisIndependent statistical analysis of Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01976741).
- Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab: Complete Statistical AnalysisIndependent statistical analysis of Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy: primary endpoint results, effect estimate with confidence…
- Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin’s Lymphomas: Complete Statistical AnalysisIndependent statistical analysis of Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Doxycycline, Temozolomide and Ipilimumab in Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Doxycycline, Temozolomide and Ipilimumab in Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01590082).
- DREAMM 5Independent statistical analysis of Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM): primary endpoint results, effect estimate with confidence interval,…
- DREAMM-3Independent statistical analysis of DREAMM-3, a randomized phase 3 trial comparing single-agent belantamab mafodotin with pomalidomide plus low-dose dexamethasone in relapsed/refractory multiple myeloma.
- DREAMM-7Independent statistical analysis of the DREAMM-7 phase 3 China subpopulation trial evaluating belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
- DREAMM-8Independent statistical analysis of DREAMM-8, a randomized phase 3 trial of belantamab mafodotin plus pomalidomide and dexamethasone versus bortezomib plus pomalidomide and dexamethasone in multiple myeloma.
- Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein: Complete Statistical AnalysisIndependent statistical analysis of DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]: Complete Statistical AnalysisIndependent statistical analysis of DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]: primary endpoint results, effect estimate…
- DUAOIndependent statistical analysis of Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related Bleeding: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00496080).
- DUARTIndependent statistical analysis of Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder: primary endpoint results, effect estimate with confidence interval, sample-size…
- DUET-2A statistical review of the phase 1 DUET-2 study of XmAb20717 in subjects with selected advanced solid tumors, including trial design, the registry-defined safety endpoint, planned statistical analysis, and interpretation of the…
- Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- DYNAMOIndependent statistical analysis of A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- e-DomSantéIndependent statistical analysis of Evaluation of Efficiency in Cancerology of New Technologies as Telemedicine and Conected Objects (e-DomSanté): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- E1199An independent statistical analysis of E1199, a randomized phase 3 trial of combination chemotherapy in women with stage II or stage IIIA breast cancer that has spread to the lymph nodes. The…
- e3Complete statistical analysis of the e3 phase 3 trial evaluating everolimus versus placebo with hormone therapy in breast cancer, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, statistical methodology, and interpretation.
- E3 Breast Cancer Taxotere Combination: Complete Statistical AnalysisIndependent statistical analysis of E3 Breast Cancer Taxotere Combination: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00494481).
- E5103Independent statistical analysis of E5103 (NCT00433511), a randomized phase 3 trial evaluating doxorubicin, cyclophosphamide, and paclitaxel with or without bevacizumab in breast cancer.
- E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS): Complete Statistical AnalysisIndependent statistical analysis of E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer: Complete Statistical AnalysisIndependent statistical analysis of E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck: primary endpoint results, effect estimate with confidence…
- E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes: Complete Statistical AnalysisIndependent statistical analysis of E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma: Complete Statistical AnalysisIndependent statistical analysis of E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- eCareIndependent statistical analysis of Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- ECHELON-2Independent statistical analysis of ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas: primary endpoint results, effect estimate with confidence…
- ECI301 and Radiation for Advanced or Metastatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of ECI301 and Radiation for Advanced or Metastatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01441115).
- ECOG 4599Independent statistical analysis of ECOG 4599 (NCT00900172), a biomarker study of patients with lung cancer treated with bevacizumab, carboplatin, and paclitaxel, including its endpoint, study design, statistical considerations, and limitations.
- EduCanIndependent statistical analysis of Effectiveness of a Modern Educational Intervention in Breast Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03351075).
- Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…